Cargando…

Erythrocyte sphingolipid species as biomarkers of Alzheimer's disease

Diagnosing Alzheimer's disease (AD) in the early stage is challenging. Informative biomarkers can be of great value for population-based screening. Metabolomics studies have been used to find potential biomarkers, but commonly used tissue sources can be difficult to obtain. The objective of thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mill, Jericha, Patel, Vihar, Okonkwo, Ozioma, Li, Lingjun, Raife, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Xi'an Jiaotong University 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073235/ https://www.ncbi.nlm.nih.gov/pubmed/35573876 http://dx.doi.org/10.1016/j.jpha.2021.07.005

Ejemplares similares

A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer’s Disease
por: Zhong, Xiaofang, et al.
Publicado: (2019)

Comparative Evaluation of MS-based Metabolomics Software and Its Application to Preclinical Alzheimer’s Disease
por: Hao, Ling, et al.
Publicado: (2018)

A fresh look at the multi‐level social determinants of disparities in Alzheimer's disease and related dementias
por: Britton, Gabrielle B., et al.
Publicado: (2023)

In-depth Site-specific Analysis of N-glycoproteome in Human Cerebrospinal Fluid and Glycosylation Landscape Changes in Alzheimer's Disease
por: Chen, Zhengwei, et al.
Publicado: (2021)

Myocardial infarction differentially alters sphingolipid levels in plasma, erythrocytes and platelets of the rat
por: Knapp, Małgorzata, et al.
Publicado: (2012)

The Impact of Cholesterol, DHA, and Sphingolipids on Alzheimer's Disease
por: Grimm, Marcus O. W., et al.
Publicado: (2013)

Effects of Aerobic Exercise Training on Systemic Biomarkers and Cognition in Late Middle-Aged Adults at Risk for Alzheimer’s Disease
por: Gaitán, Julian M., et al.
Publicado: (2021)

Sphingolipid Catabolism and Glycerophospholipid Levels Are Altered in Erythrocytes and Plasma from Multiple Sclerosis Patients
por: Momchilova, Albena, et al.
Publicado: (2022)

β-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer’s disease pathology
por: Shippy, Daniel C., et al.
Publicado: (2020)

Involvement of Huanglian Jiedu Decoction on Microglia with Abnormal Sphingolipid Metabolism in Alzheimer’s Disease
por: Qi, Yi-Yu, et al.
Publicado: (2022)

The Role of Sphingolipids and Specialized Pro-Resolving Mediators in Alzheimer’s Disease
por: de Wit, Nienke M., et al.
Publicado: (2021)

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
por: Van Hulle, Carol, et al.
Publicado: (2020)

Changes in Phospholipid Composition of Erythrocyte Membrane in Alzheimer's Disease
por: Oma, Shinji, et al.
Publicado: (2012)

Crosswalk study on blood collection‐tube types for Alzheimer's disease biomarkers
por: Jonaitis, Erin M., et al.
Publicado: (2022)

The Equilibria of Sphingolipid-Cholesterol and Sphingolipid–Sphingolipid in Monolayers at the Air–Water Interface
por: Petelska, Aneta Dorota, et al.
Publicado: (2012)

Sphingolipid Metabolism Correlates with Cerebrospinal Fluid Beta Amyloid Levels in Alzheimer’s Disease
por: Fonteh, Alfred N., et al.
Publicado: (2015)

In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer’s disease
por: Levin, Fedor, et al.
Publicado: (2021)

Sphingolipids in neurodegenerative diseases
por: Pan, Xueyang, et al.
Publicado: (2023)

Comparative assessment of erythrocyte sphingolipid levels as potential cardiovascular health markers in women from Libya and Serbia: a small-scale study
por: Vidović, Nevena, et al.
Publicado: (2023)

Exercise Effects on Cognitive Function in Humans
por: Okonkwo, Ozioma, et al.
Publicado: (2019)

Accumulation of Cerebrospinal Fluid Glycerophospholipids and Sphingolipids in Cognitively Healthy Participants With Alzheimer’s Biomarkers Precedes Lipolysis in the Dementia Stage
por: Fonteh, Alfred N., et al.
Publicado: (2020)

Alterations of Sphingolipid and Phospholipid Pathways and Ornithine Level in the Plasma as Biomarkers of Parkinson’s Disease
por: Chang, Kuo-Hsuan, et al.
Publicado: (2022)

Erythrocytes as Potential Link between Diabetes and Alzheimer’s Disease
por: Carelli-Alinovi, Cristiana, et al.
Publicado: (2017)

Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?
por: Mah, Michael, et al.
Publicado: (2021)

The Dark Side of Sphingolipids: Searching for Potential Cardiovascular Biomarkers
por: Di Pietro, Paola, et al.
Publicado: (2023)

Cardiorespiratory fitness mitigates brain atrophy and cognitive decline in adults at risk for Alzheimer's disease
por: Dougherty, Ryan J., et al.
Publicado: (2021)

Heritability of Protein and Metabolite Biomarkers Associated with COVID-19 Severity: A Metabolomics and Proteomics Analysis
por: Haj, Amelia K., et al.
Publicado: (2022)

Lipid Profiling of Alzheimer’s Disease Brain Highlights Enrichment in Glycerol(phospho)lipid, and Sphingolipid Metabolism
por: Akyol, Sumeyya, et al.
Publicado: (2021)

The Enigma of Sphingolipids in Health and Disease
por: Kleuser, Burkhard
Publicado: (2018)

Sphingolipids in thyroid eye disease
por: Gulbins, Anne, et al.
Publicado: (2023)

Clinical Sphingolipids Pathway in Parkinson’s Disease: From GCase to Integrated-Biomarker Discovery
por: Esfandiary, Ali, et al.
Publicado: (2022)

Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease
por: Goozee, Kathryn, et al.
Publicado: (2017)

Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease
por: Law, Lena L., et al.
Publicado: (2018)

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
por: Savica, Rodolfo, et al.
Publicado: (2016)

Sphingolipid Analysis Indicate Lactosylceramide as a Potential Biomarker of Inflammatory Bowel Disease in Children
por: Filimoniuk, Aleksandra, et al.
Publicado: (2020)

Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
por: Ma, Yue, et al.
Publicado: (2021)

Metabolic Abnormalities of Erythrocytes as a Risk Factor for Alzheimer's Disease
por: Kosenko, Elena A., et al.
Publicado: (2018)

Plasma sphingolipid abnormalities in neurodegenerative diseases
por: Oizumi, Hideki, et al.
Publicado: (2022)

Integrated Systems Approach Reveals Sphingolipid Metabolism Pathway Dysregulation in Association with Late-Onset Alzheimer’s Disease
por: Malamon, John Stephen, et al.
Publicado: (2018)

Brain Glucose Metabolism, Cognition, and Cardiorespiratory Fitness Following Exercise Training in Adults at Risk for Alzheimer’s Disease
por: Gaitán, Julian M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jr8rigom3vdhdhskn540h5to8e